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Purpose. In the present study, the salivary melatonin secretion in the hypoxic ischemic encephalopathy (HIE) children was
measured. *e logit model was fitted to the data to obtain the salivary dim light melatonin onsets (DLMOs), and the results
were compared with the values estimated from the classic threshold method with a linear interpolation and those previously
published for the blood measurements.Materials and Methods. 9 patients suffering from HIE aged from 65 to 80 months were
included in the study. *e melatonin levels were assessed by a radioimmunoassay (RIA). *e diurnal melatonin secretion was
estimated using a nonlinear least squares method. Student’s t-test and theMann–WhitneyU test were used for the comparisons
of the obtained parameters. Results. *e circadian profiles of the melatonin secretion for both calculation methods do not differ
statistically.*e DLMO parameters obtained in the blood and saliva samples in children with hypoxic ischemic encephalopathy
were similar.
1. Introduction
Melatonin (N-acetyl-5-methoxytryptamine), secreted mainly
by the pineal gland, but synthesized also in many other tissues
and cells, diffuses into blood plasma and saliva, where it can
be measured experimentally. Because it is involved in the
regulation of circadian rhythms, such as the sleep-wake
rhythm, neuroendocrine rhythms, or body temperature cy-
cles, the disturbances of its secretion are considered an early
indicator of certain disorders and also the biomarker of their
follow-up [1]. *e most commonly reported phase marker of
the melatonin secretion is the DLMO—the dim light mela-
tonin onset [2]. In physiological condition, it is particularly
convenient, since it can usually be obtained about 2 to 3 hours
prior to a habitual sleep.
In our previous studies, we showed that melatonin se-
cretion in children with hypoxic ischemic encephalopathy
(HIE) is significantly disturbed, even stronger than in epi-
lepsy. Its characteristic features, as seen from the blood
sampling [3, 4], are the delayed melatonin phase release and
the shift of the DLMO parameters to the later morning
hours.
*e mathematical modelling of the circadian melatonin
cycle was used by us to objectify the description of the
melatonin secretion in blood [5]. Although many mathe-
matical models are used to obtain the information on the
circadian phase from the plasma melatonin rhythm [6], they
may be insufficient when modelling the salivary melatonin
secretion due to much lower concentration of melatonin in
saliva than in the plasma. Moreover, because taking the
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saliva samples without disturbing a sleeping individual is
difficult, the estimates may be of lower resolution, and in
consequence, the lack of data from the entire time of
melatonin secretionmakes it impossible to use any threshold
calculation that depends on the overall amplitude of the
pulse [7].
Most of the modelling methods depend on curve-fitting
of the melatonin profile and/or the crossing of a threshold to
determine phase. *e simple threshold interpolation is one
of the most widely used for the DLMO description in en-
dogenous melatonin secretion [8, 9], though it is claimed to
be less accurate than the more flexible curve-fitting models
[10, 11].
In saliva, the phase estimates are usually calculated by the
same curve-fitting and threshold methods as for plasma
melatonin, but the nonlinear shape of melatonin secretion
and missing data may lead to the contradictory results.
*erefore, more complex interpolations, biophysical models
fitting, or the differential equation methods were introduced
in the circadian rhythm analysis [4, 10, 12].
In our previous work [5], we applied a bell-shaped
function to model the melatonin secretion in blood in the
HIE children—such modelling requires a complete mela-
tonin curve to calculate the DLMOs. *e logit model pro-
posed in this work makes it possible to estimate the DLMO
parameters with a shorter melatonin collection time.
We used such model to fit to the melatonin salivary
secretion onsets in the HIE children, and its results were
compared with those obtained from the classic threshold
method with linear interpolation. *en, the estimates of the
salivary DLMO parameters were compared with the blood
values from the previous study [5].
2. Materials and Methods
*e study was approved by the Ethic Committee of the
Medical University of Silesia in Katowice. *e informed
written consent was taken from the parent or caregivers. *e
study was carried out at the Department of Pediatric
Neurology, School of Medicine in Katowice, the Medical
University of Silesia in Katowice.
2.1. Patients. 9 patients suffering from hypoxic ischemic
encephalopathy aged from 61 to 82 months (mean age 5.92
years, SD± 0.56) were included in the study from the group
of 19 patients. 10 patients were rejected at the initial stage of
the data analysis due to the missing data from the rising part
of the salivary melatonin onset—in such cases, the phase
markers could not be calculated.
*e demographic characteristics of the participants are
shown in Table 1. *e recruitment procedure of the study
group was the same as described in our previous work [5].
Before and during the experimental period, the subjects
were not administered the medications affecting melatonin
secretion, such as benzodiazepines and their antagonists,
fluvoxamine, caffeine, vitamin B12, and nonsteroidal anti-
inflammatory drugs (aspirin, ibuprofen, indomethacin,
adrenolytics, prostaglandins inhibitors, calcium channel
blockers, dexamethasone, and antidepressants). Further-
more, the legal guardians of the patients were instructed not
to use a toothpaste or mouthwash during the assessments.
In 3 patients, the epileptic seizures did not occur on the
day or the day before the melatonin measurements, and 6
children had them on the day of sampling.*e amplitudes of
the melatonin release were estimated for these patients using
a nonparametric Mann–Whitney U test, and no statistical
significance was found (p � 0.3662).
2.2. Experimental Design. In order to determine the mela-
tonin concentration and its circadian excretion profile, all
subjects had their saliva taken every hour starting from 17:00
till 7:00 am. Saliva was collected in dim red light (10 lux) into
the Salivette tubes (Sarstedt, Germany) by chewing on a
cotton swab for 1-2min. *e sampling took place during the
hospitalization at the Department of Pediatric Neurology,
Medical University of Silesia in Katowice. During the col-
lection, the patients stayed in a darkroom. *e use of tablets
and cells was prohibited.
*e collected samples were shipped in dry ice to the
laboratory to be radioimmunoassayed for melatonin detec-
tion. *e experiment was performed under a dim light
condition.*e enzyme-linked immunosorbent assay (ELISA)
method was used. *e lower limit of sensitivity was deter-
mined by interpolating the mean optical density minus 2 SDs
of 30 sets of duplicates at the 0 pg/mL level. *e minimal
concentration of melatonin that can be distinguished from 0
was 1.37 pg/mL. *e functional sensitivity of the assay (Sal-
ivary Melatonin EIA Salimetrics) was 1.42 pg/ml, and the
intra- and interassay coefficients of the variabilities were 0.2%
and 16.6%, respectively.
2.3. Data Analysis. *e circadian timing was determined by
calculating the DLMO values as the marker of the individual
circadian clock and in particular as an indicator of the
beginning of the internal biological night. Moreover, the
minimum and maximum melatonin concentrations were
also calculated [8, 11, 13].
2.3.1. Melatonin Secretion Parameters: Curve-Fitting
Method. In order to describe the nonlinear character of the
melatonin onset, the three parameter logit estimation was
applied to the data [4, 10]. Due to the changes in the
melatonin secretion amplitudes in pediatric patients, the
relative thresholds were used in the melatonin profiles de-
scription to normalize the amplitude differences and facil-
itate the comparisons [2, 10].
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*e melatonin secretion parameters were normalized,
and their biophysical interpretation is as follows:
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(1) b1 is a melatonin release amplitude (pg/mL), where
the amplitude is the difference between the mini-
mum and maximum melatonin concentrations
(2) b2 (DLMO50E) denotes the time at which amelatonin
level exceeds 50% amplitude (h), and E indicates the
method of determining the parameter (E-estimation)
(3) b3 is a minimum melatonin concentration (pg/mL)
from a range <0, +∞)
(4) *e maximum melatonin concentration bmax is a
sum of b1 and b3
*e dim light melatonin onset 25% (the time at which a
melatonin level exceeds 25% amplitude) was calculated
using equation (1):
DLMO25E � b2 − ln(3). (2)
*e phase and amplitude parameters may have different
meanings in some situations depending on the used
methods in secretion profile analysis [4, 5, 10, 14–17]. *us,
Figure 1 presents the graphical representation of the mel-
atonin secretion model and visualizes the biophysical
meaning of its parameters.
*is set of parameters was estimated in order to define a
melatonin cycle in saliva. *e data were fitted with a
nonlinear least squares fitting analysis based upon the
Levenberg–Marquardt method in Statistica 12 software.
*e quality of the obtained models was verified by the
normality test of the residuals’ distribution, the statistical
significances of the estimated parameters, the percentage of
the explained variance (>80%), and the R value (>0.89).
2.3.2. Melatonin Secretion Parameters: :reshold-Based
Method with Linear Interpolation. *e salivary DLMO was
also determined using the threshold-based methods that
depend on the crossing of a predetermined melatonin
concentration. A linear interpolation was used to determine
the threshold-crossing time. *e relative threshold of the
25th and 50th percentiles of the melatonin amplitude were
chosen to obtain DLMO25I and DLMO50I, respectively (the
I index denotes that the parameters were obtained via
interpolation).
*e minimum and maximum melatonin concentrations
correspond to the lowest and highest values in the measured
secretion profile, respectively.
2.3.3. Statistical Comparison of the Melatonin Secretion.
*e obtained melatonin parameters (the minimum and
maximum melatonin concentrations and the DLMO pa-
rameters) were interpreted in terms of their biophysical
and clinical meaning and analyzed using Statistica 12
software. In order to compare the estimated (a curve-fitting
method) secretion parameters with those obtained with the
threshold-based method (with a linear interpolation),
Student’s t-test was used. Since, for the minimum mela-
tonin concentration, the individual groups do not meet the
requirements for the parametric tests (the data were not
normally distributed), a nonparametric Mann–Whitney U
test was used.
Finally, the salivary melatonin DLMO parameters esti-
mated using the curve-fitting method were compared with
those obtained from the blood samples of the HIE patients
[5].
*e values less than 0.05—a predetermined signifi-
cance level—were accepted as indicating that the ob-
served result would be highly unlikely under the null
hypothesis.
Table 1: Patients’ characteristics: age 65–80 months and mean age 6 years.
Family history
Nonremarkable, N� 3 (33.3%)
Hypothyroidism, N� 2 (22.2%)
Developmental delay, N� 2 (22.2%)
Epilepsy, N� 1 (11.1%)
Attention deficit hyperactivity disorder, N� 1 (11.1%)
Gestation and delivery period (abnormalities)
Preterm delivery, N� 9 (100%)
Cesarean section, N� 9 (100%)
Low birth weight, N� 9 (100%)
Psychomotor development
Retarded, N� 9 (100%)
Mild intellectual disability, N� 4 (44.4%)
Moderate intellectual disability, N� 3 (33.3%)
Severe intellectual disability, N� 2 (22.2%)
Neurological examination
Spastic diplegia, N� 3 (33.3%)
Right hemiparesis, N� 2 (22.2%)
Left hemiparesis, N� 2 (22.2%)
Spastic tetraplegia, N� 2 (22.2%)
Electroencephalography Generalized paroxysmal changes, N� 9 (100%)
Seizures’ morphology Myoclonic seizures (MS), N� 9 (100%)Tonic-clonic seizures (GTCS), N� 9 (100%)
Antiepileptic treatment Valproic acid (VPA), N� 9 (100%)Levetiracetam (LEV), N� 9 (100%)
Brain MRI Periventricular leukomalacia (PVL), N� 9 (100%)
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3. Results
*e salivary melatonin onset curves were approximated for
each patient separately, and the illustrative example of the
estimated model obtained for a representative patient with
hypoxic ischemic encephalopathy is shown in Figure 2.
*e approximated parameters are b1 � 60,07 (pg/mL);
b2 � 24.65 (h); b3 � 4.05 (pg/mL); bmax � 64.12 (pg/mL);
and DLMO25 � 23.26 (h).
3.1. Comparison of the Salivary Melatonin Secretion Param-
eters Calculated from the Curve-Fitting and :reshold-Based
(with a Linear Interpolation) Methods. *e salivary mela-
tonin secretion profiles (DLMO50, DLMO25, and maxi-
mum and minimum melatonin concentrations) estimated
by the curve-fitting method were compared with that ob-
tained using the traditional threshold-based method with a
linear interpolation. *e statistical analysis was performed
using Student’s t-test, and the results are presented in Ta-
bles 2 and 3. Moreover, the minimum melatonin concen-
trations were compared using Mann–Whitney–Wilcoxon
because the requirements for the parametric tests were not
fulfilled for this variable (the data were limited and not
normally distributed).
3.2. Comparison of the Salivary and Blood Melatonin DLMO
Parameters in Hypoxic Ischemic Encephalopathy. *e sali-
vary DLMO parameters obtained using a curve-fitting
method were compared with those obtained from the blood
secretion profiles also for the HIE group from our previous
study [5] (Table 4). *e results show more evidence for the
null hypothesis of no difference of the salivary and blood
DLMOs in the HIE groups. *e statistical analysis of the
other concentration parameters was not performed due to
the expected significant disproportion of the melatonin
concentrations values in both biofluids.
4. Discussion
Determination of the melatonin levels in saliva is the most
popular method, due to its ease, relatively low invasiveness,
and a relationship between the circadian changes of the
melatonin concentration in saliva and the melatonin vari-
ations in plasma [18] or serum [19–21]. Also, the urinary
excretion of 6-sulphatoxymelatonin (aMT6s), the major
melatonin metabolite in humans, is proved to oscillate
consistently with melatonin concentration in plasma and
saliva [2, 22].
As we found in the PubMed database, in the last decade,
the salivary melatonin measurements were mentioned in
about 57% of the papers concerning the melatonin secretion,
whereas about 25% related to its evaluation in blood or
serum and about 18% in urine. *e concentration of mel-
atonin in saliva is 24–33% of the plasma melatonin (this
percentage reflects the free melatonin fraction, not related to
albumin), making its routine determination an analytical
challenge [18, 23, 24]. Due to the volume differences of
plasma and saliva, the interindividual differences in sensi-
tivity to the light, a diurnal variation in melatonin synthesis,
and the effects associated with the continuous production of
saliva and low salivary melatonin concentrations, the sali-
vary melatonin sampling is of lower resolution and sensi-
tivity than in case of blood [2, 25]. Moreover, the salivary
measurements are associated with the limitations resulting
from eating, drinking, and oral hygiene measures that could
falsify the results.
*us, taking into account the evident quantitative ad-
vantage of the salivary measurements over those in other
biofluids, but at the much lower accuracy of the salivary
melatonin profile estimates, one may ask whether the latter
are reliable and what is the actual correspondence of the
results obtained for various biofluids. *ough such com-
parisons are available for healthy subjects [26], there is a
sparse number of the papers on the correlation between the
salivary and blood melatonin levels in HIE children
[2, 6, 27]. In our study, the salivary DLMO parameters



























Figure 2: *e salivary melatonin onset for the exemplary patient
with hypoxic ischemic encephalopathy—the estimated model; and






















Figure 1: *e melatonin secretion model. *e solid line shows the
curve-shaped function approximating the melatonin secretion with
the following parameters: b1 is the melatonin release amplitude; b2
is DLMO50E; b3 is the minimum melatonin concentration; and
dotted line is the minimum melatonin concentration level.
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obtained for the HIE children were compared with the blood
phase markers of the children with the same diagnosis [5].
As revealed from the comparison, the DLMO values are
consistent showing that the circadian melatonin phase
markers in blood and saliva for the children with hypoxic
ischemic encephalopathy are similar. Additionally, for both
data sets, the curve-fitting method was applied in the DLMO
calculations. Unfortunately, the differences in the data
collection procedures did not allow to use one circadian
model. However, when using different fitting curves in the
estimation process, one must be aware that it may result in
the uncertainties of the determined values. On the other
hand, due to the frequent limitations of the saliva and blood
collection methods, one universal melatonin secretion
modelling method seems to be unavailable. *erefore, to
facilitate the comparisons of the results and to verify them,
some comparative testing should be applied [2], and in our
study, the comparison of the salivary parameters with the
blood melatonin ones plays such role. *ough the saliva and
blood samples were collected for two separate HIE groups,
the inclusion criteria for the children with the same clinical
diagnosis were the same.
In the estimations, we focused on the DLMO, as themost
accepted and reliable circadian phase marker, claimed to be
more reliable than DLMOoff (the dim light melatonin offset)
and the phase markers derived from the core body tem-
perature rhythm [11, 15]. On the other hand, the most
diversity in the published methods occurs with determi-
nation of the onset of melatonin secretion. *e main hy-
pothesis of our work was that the DLMO parameters
obtained via the estimation and interpolation methods are
compatible. Moreover, since the full salivary melatonin
profiles without missing data are usually difficult to be
obtained, we tested the ability of the simplified model to
predict the rising part of the melatonin synthesis onset
accurately. Two methods of the DLMO determination from
the salivary melatonin measurements in the HIE patients
were compared: the threshold-based interpolation and the
curve-fitting method. *e logit model has been developed to
describe the onset part of the melatonin secretion cycle. *e
statistical analysis of the results confirmed the consistency of
the circadian parameters estimated in both methods. As
expected, the melatonin salivary data are highly spread,
especially during the night part of the cycle. Due to the
observed fluctuations, the criteria for the model quality
acceptance were lowered (the percentage of the explained
variance (>80%) and the R value (>0.89)) compared to the
literature data [5, 16, 28].
*e fitting method is useful when other methods of the
melatonin cycle description are either impossible or im-
practical [5, 10, 16, 17, 28], in case of difficult (a large
statistical spread) or incomplete data, where the bell-shaped
model, as the more demanding, cannot be applied [5].
Unfortunately, due to the simplicity of the logit function, it
does not allow to estimate DLMOoff or to indicate the lo-
cation of the release amplitude and calculate the duration of
the night melatonin release [4].
*e individual differences in the sleep/wake schedules can
be also analyzed and described in terms of the patient’s
chronotype. Because the circadian clocks vary with the sex,
age, the genetic background [29], and light exposure [30], the
Morningness-Eveningness Chronotype Questionnaires, such
as the Munich ChronoType Questionnaire (MCTQ) [31], the
Morningness-Eveningness Questionnaire (MEQ) [32], or the
Morningness-Eveningness Scale for Children (MESC) [33],
may be applied as a simplified estimate of the circadian
timing. Importantly, the chronotypes assessed with them are
generally strongly correlated with DLMO [34], both in adults
Table 3: Comparison of the curve-fitting and threshold-based (with a linear interpolation) methods—the minimum melatonin
concentrations.
Median for curve-fitting method Median for threshold-based method p value∗
Minimum melatonin concentration (pg/mL) 2.6433 0.7800 0.7239
∗Mann–Whitney U test.
Table 4: *e comparison of the DLMO parameters obtained from the salivary and blood melatonin secretion profiles.
Median for the saliva samples Median for the blood samples p value∗∗
DLMO50 (h)∗ 22.29 22.85∗∗∗ 0.2510
DLMO25 (h)∗ 21.19 21.90∗∗∗ 0.2893
∗Time in the decimal scale. ∗∗Mann–Whitney U test. ∗∗∗Data from Paprocka et al., 2018.
Table 2: Comparison of the curve-fitting and threshold-based (with a linear interpolation) methods—the DLMO50, DLMO25,
and maximum and minimum melatonin concentrations.
Average for the curve-fitting
method
Average for the threshold-based
method p value
∗∗
DLMO50 (h)∗ 22.0206 21.9499 0.9437
DLMO25 (h)∗ 20.6897 20.8979 0.8415
Maximum melatonin concentration
(pg/mL) 63.7445 67.5920 0.7816
∗Time in the decimal scale; ∗∗Student’s t-test.
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[35] and in healthy school-aged children and adolescents
[36–38], but the reports on infants are scarce [39, 40].
According to Simpkin et al. and Randler et al. [39, 40], in the
toddler age, there is a prevalence of the morning types, but
during the next years of age, a progressive delay in chronotype
takes place [39], and finally, each type of chronotype can be
seen in the preschool children [36, 39, 41]. *e differences
between the morning and evening chronotypes are seen as a
shift of the DLMO values towards the night hours [35]. *e
morning-type individuals have earlier sleep-wake schedules,
earlier diurnal peaks of alertness and performance, and earlier
sleep propensity rhythms than the evening-type individuals
[42]. On the other hand, an accumulating evidence suggests
that there is a feedback between the epileptic seizures and the
circadian rhythms—in its consequence, the seizure timing
influences the timing of the daily activities, sleeping, and
wakefulness, i.e., the chronotype [4, 16, 43] showed that the
phase shift of the melatonin release occurs later in the epi-
leptic patients and found that there is a significant relationship
between a phase shift of the melatonin peak and the seizures.
However, the supporting studies with the application of the
chronotype questionnaires were not performed in that study.
Our current results confirm the previous observations, as in
the HIE children, the DLMO50 and DLMO25 values are
shifted to the late night hours too. In accordance with the
previous findings, also in this study, in 6 patients (66.6% of the
studied group), the epileptic seizures occurred on the day of
the melatonin sampling, leading the melatonin secretion in
children with hypoxic ischemic encephalopathy to be strongly
disturbed. *us, the obtained results point towards the
supposition that, in the HIE children, the evening-type
chronotype may dominate. However, the studied group is too
small (9 subjects), and the salivary measurements were not
supported by the chronotype questionnaire analyses, leaving
such supposition uncertain. Because the reports concerning
the influence of antiepileptic drugs on the melatonin levels in
saliva and plasma of pediatric patients are ambiguous
[44–46], we decided not to exclude the patients due to the
treatment applied. Along with the small group size, it is the
main drawback of the study, but as shown in Tables 2–4, no
statistically significant differences between the biofluids and
the methods were found. A larger study, based upon the
mathematical modelling of the whole melatonin profiles and
with application of the chronotype questionnaires, would be
necessary to gain a better insight into the disturbances of the
circadian rhythms in HIE patients and of their chronotype.
*e main disadvantage of the saliva sampling is the lack
of the standardized sampling protocols and the standardized
normative values enabling the comparison of the results in
the tested groups, especially in young children or in epileptic
children. In our study, the saliva and blood samples were
taken every 1 hour which, according to Crowley et al., allows
to estimate the DLMO as accurately as in case for a sampling
time of 0.5 hour [47].
Abeysuriya et al. indicate that development of
modelling will open new possibilities to calculate and
compare the melatonin secretion profiles independently
of the biomaterial being tested [26]. Such modelling may
allow to establish the normative values for melatonin. We
hope that our comparative two-model mathematical
approach to evaluation of the melatonin secretion pa-
rameters (DLMO) in two biofluids brings us closer to
such solution and underlines the role of mathematical
modelling.
Generally, higher sampling rate and more data streams
used for fitting are necessary to obtain more accurate
prospective predictions.
5. Conclusions
In this study, we compared the basic parameters of mela-
tonin secretion calculated using the curve-fitting method
and the popular threshold method (with a linear interpo-
lation). We showed that the results do not differ statistically,
which, in our opinion, argues in favor of using a simple and
well-known method being more resistant to imperfect
sampling.
Moreover, we compared the results of the determined
time parameters (DLMO25 and DLMO50) with those ob-
tained in the blood melatonin measurements from our
previous work [5]. Despite the differences in the nature of
these biofluids and the sampling schemes (regular blood
measurements vs. frequent incomplete data in saliva), we
showed that the results of the examined parameters do not
differ statistically. In both studies, the different mathematical
models were used, but the obtained DLMO parameters agree
and do not differ statistically, which allows us to conclude
that they could be used interchangeably as needed.
Data Availability
*e datasets generated for this study are available from the
corresponding author upon request.
Conflicts of Interest
*e authors declare that there are no conflicts of interest
regarding the publication of this paper.
Acknowledgments
*e authors would like to thank the Institutional Grant of
the Medical University of Silesia (no. PCN-1-195/K/9/K) for
their support.
References
[1] S. Tordjman, S. Chokron, R. Delorme et al., “Melatonin:
pharmacology, functions and therapeutic benefits,” Current
Neuropharmacology, vol. 15, no. 3, pp. 434–443, 2017.
[2] S. Benloucif, H. J. Burgess, E. B. Klerman et al., “Measuring
melatonin in humans,” Journal of Clinical Sleep Medicine,
vol. 4, no. 1, pp. 66–69, 2008.
[3] J. Paprocka, M. Kijonka, and M. Sokół, C. M. Drăgoi and
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